Opus Genetics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Opus Genetics, Inc. (IRD) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 886.96 thousand shares for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-24.
Discontinued › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2017-02-24
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2016-12-31 was 803.63K shares, a 243.80% increase year-over-year.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2016-09-30 was 0.00 shares.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2015-12-31 was 233.75K shares.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2013-12-31 was 0.00 shares.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2016 was 886.96K shares, a 133.51% increase from fiscal 2015.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2015 was 379.83K shares.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2013 was 85.00K shares, a 43.33% decline from fiscal 2012.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2012 was 150.00K shares, a 78.48% decline from fiscal 2011.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2016-12-31 | 803.63K shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-24 | 803.63K shares derived: sum of 2 quarters · filed 2017-02-24 | 886.96K shares 10-K · filed 2017-02-24 | |
| 2016-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | 83.33K shares 10-Q · filed 2016-11-04 | ||
| 2016-06-30 | 83.33K shares 10-Q · filed 2016-08-05 | |||
| 2015-12-31 | 233.75K shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | 379.83K shares 10-K · filed 2016-03-14 | ||
| 2015-09-30 | 146.08K shares 10-Q · filed 2015-11-02 | |||
| 2013-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | 85.00K shares 10-K · filed 2015-03-16 | ||
| 2013-09-30 | 85.00K shares 10-Q · filed 2014-11-12 | |||
| 2012-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-21 | 100.00K shares derived: sum of 2 quarters · filed 2014-03-21 | 109.00K shares derived: sum of 3 quarters · filed 2014-03-21 | 150.00K shares 10-K · filed 2014-03-21 |
| 2012-09-30 | 100.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-13 | 109.00K shares derived: sum of 2 quarters · filed 2013-11-13 | 150.00K shares 10-Q · filed 2013-11-13 | 655.00K shares derived: sum of 4 quarters · filed 2013-11-13 |
| 2012-06-30 | 9.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-12 | 50.00K shares 10-Q · filed 2013-08-12 | 555.00K shares derived: sum of 3 quarters · filed 2013-08-12 | 658.00K shares derived: sum of 4 quarters · filed 2013-08-12 |
| 2012-03-31 | 41.00K shares 10-Q · filed 2013-05-09 | 546.00K shares derived: sum of 2 quarters · filed 2013-05-09 | 649.00K shares derived: sum of 3 quarters · filed 2013-05-09 | |
| 2011-12-31 | 505.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-22 | 608.00K shares derived: sum of 2 quarters · filed 2013-03-22 | 697.00K shares 10-K · filed 2013-03-22 | |
| 2011-09-30 | 103.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | 192.00K shares 10-Q · filed 2012-11-08 | ||
| 2011-06-30 | 89.00K shares 10-Q · filed 2012-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |